TITLE

Biogen Rises On MS Drug OK

AUTHOR(S)
Investor's Business Daily
PUB. DATE
March 2013
SOURCE
Investors Business Daily;3/28/2013, pA01
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
4 The FDA approved Tecfidera, widely expected to become the top oral drug for multiple sclerosis, with annual sales over $3 bil. The drug, previously known as BG-12, cut the average relapse rate by 49% after 2 years, clinical data showed. Tecfidera will compete with Novartis' ([STOCK[NVS]]) Gilenya and
ACCESSION #
86416072

 

Related Articles

  • Sales force triggered Tysabri uptick. Comer, Ben // Medical Marketing & Media;Dec2010, Vol. 45 Issue 12, p16 

    The article focuses on the 15 percent increase of revenues of Biogen Idec in the U.S. because of Elan's MS drug Tysabri.

  • Pent-up demand should drive Tecfidera, docs say. McCaffrey, Kevin // Medical Marketing & Media;May2013, Vol. 48 Issue 5, p10 

    The article reports on high demands towards multiple sclerosis (MS) drug, Tecfidera, from Biogen Idec Inc.

  • Biogen Idec files European MAA for multiple sclerosis drug.  // PharmaWatch: Biotechnology;Mar2010, Vol. 9 Issue 3, p12 

    The article reports on the submission of marketing authorization application (MAA) by Biogen Idec to the European Medicines Agency (EMA) for its multiple sclerosis (MS) drug Fampridine.

  • Orphan Competition.  // Pharmaceutical Executive;Apr2002, Vol. 22 Issue 4, p24 

    Focuses on the approval won by Geneva, Switzerland-based Serono to market its multiple sclerosis (MS) therapy, Rebif, in the U.S. Impact of the approval on the stock of Biogen's MS drug Avonex in the U.S.

  • Multiple Sclerosis.  // PharmaWatch: CNS;November 2003, Vol. 2 Issue 11, p17 

    Reports on developments relating to multiple sclerosis (MS) treatment. Phase II of Active Biotech's multiple sclerosis drug; Positive long-term results for MS patients shown by Serono's Rebif drug; Study showing long-term effect of Biogen's MS drug.

  • Clinical studies position drugs in multiple sclerosis market.  // Medical Marketing & Media;Jun2000, Vol. 35 Issue 6, p16 

    Highlights outcomes of clinical studies of drugs for use on multiple sclerosis (MS). Biogen's phase III trial of the interferon beta-1a drug, Avonex; Prescription of Chiron Corp.'s Betaseron for relapsing MS; Teva Marion's Copaxone; Immunex's filing of supplemental new drug application for...

  • How Tysabri survived. Huggett, Brady // Nature Biotechnology;Nov2009, Vol. 27 Issue 11, p986 

    The author considers the success of Biogen Idec in reintroducing its multiple sclerosis (MS) drug Tysabri in the U.S. The author says the company pulled the drug from the market after its association with the development of progressive multifocal leukoencephalopathy (PML) has been confirmed. He...

  • Biogen and Abbott Start Phase III Trial of MS Antibody Daclizumab. Morrison, Trista // BioWorld Today;5/25/2010, Vol. 21 Issue 100, p1 

    The article reports that Biogen Idec Inc. and Abbott have begun their Phase III trial comparing their anti-interleukin-2 antibody daclizumab to Biogen's Avonex in relapsing-remitting multiple sclerosis (MS) in May 2010. It offers information on the mechanism of action of daclizumab. The clinical...

  • Multiple Sclerosis: We've Got Your Number. Comer, Ben // Pharmaceutical Executive;Nov2012, Vol. 32 Issue 11, p34 

    The article explores the history and progress of drug development for multiple sclerosis (MS). It cites the first disease-modifying drugs that entered market for MS in 1990s such as Betaseron, Avonex, and Copaxone. Moreover, it highlights the development Biogen Idec Inc.'s BG-12, one of the most...

  • Elan: Antegren approval will be a lifeline.  // PharmaWatch: Monthly Review;September 2004, Vol. 3 Issue 9, p18 

    Reports on Biogen Idec and Elan's collaboration to produce Antegren for multiple sclerosis (MS) treatment. Overview on the financial performance of Biogen and Elan for the second quarter of 2004; U.S. Food and Drug Administration's formal acceptance of the biologic license application for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics